Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, overexpression of human ZnT8 diabetes high-risk allele R325W increased 5-HT levels relative to the low-risk allele in RIN14B cells.
|
30936149 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease.
|
30783963 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other outcomes are: (1) Any persistent confirmed beta-cell autoantibody (glutamic acid decarboxylase (GADA), IA-2A, autoantibodies to insulin (IAA) and zinc transporter 8 or tetraspanin 7), or diabetes, (2) Persistent confirmed IAA, (3) Persistent confirmed GADA and (4) Abnormal glucose tolerance or diabetes.
|
31256036 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we summarize the structure, feature, functions, and polymorphisms of ZnT8 along with its association with diabetes and explore future study directions.
|
30936916 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, those with later onset type 1 diabetes had a modestly lower type 1 diabetes genetic risk score (0.268 vs 0.279; p < 0.001 [expected type 2 diabetes population median, 0.231]), a higher islet autoantibody prevalence (GAD-, islet antigen 2 [IA2]- or zinc transporter protein 8 [ZnT8]-positive) of 78% at 13 years vs 62% at 26 years of diabetes duration; (p = 0.02), and were less likely to identify as having type 1 diabetes (79% vs 100%; p < 0.001) vs those with young-onset disease.
|
30969375 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion.
|
31676859 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Susceptibility Gene SLC30A8 that Encodes the Zinc Transporter ZnT8 is a Pseudogene in Guinea Pigs Potentially Contributing to Low Guinea Pig Islet Zinc Content.
|
30392157 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab are associated with more acute diabetes onset.
|
29327148 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab positive patients had higher titre and more frequent occurrence of multiple diabetes-related autoantibodies than ZnT8-ab negative patients.
|
30465779 |
2018 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C-terminal cytosolic domain of the human zinc transporter ZnT8 and its diabetes risk variant.
|
29430817 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, Znt8 Arg-325 risk variant shows an enhanced inflammatory response upon LPS stimulation that might aggravate insulin resistance and the progression of diabetes cardiovascular complications.
|
30142362 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The breakthrough discovery that the common polymorphism in zinc transporter <i>SLC30A8</i>/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes.
|
29415457 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 31 Somali children ≤19 yr were treated for type 1 diabetes (T1D) at the University of Minnesota Masonic Children's Hospital and Children's Hospitals and Clinics of Minnesota underwent analysis of human leukocyte antigen (HLA) alleles (n = 30) and diabetes autoantibodies [glutamic acid decarboxylase (GAD65), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8); n = 31].
|
26854192 |
2017 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The majority of multiple-autoAb<sup>+</sup> individuals progress to diabetes within 20 years; this occurs more rapidly in the presence of IA-2A or ZnT8A, regardless of age, <i>HLA-DQ</i> genotype, and number of autoAbs.
|
28701370 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 97 subjects with diabetes onset before age 25, a random C-peptide ≥0.1 ng/mL, and negative for all diabetes autoantibodies (GADA, IA-2, ZnT8, and IAA) were enrolled, after excluding 21 subjects with secondary diabetes or refusal to participate.
|
26059258 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis.
|
26519333 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we summarize the literature about clinical aspects of ZnT8 in the pathogenesis of diabetes, and suggest that ZnT8 might play a different role between type 1 diabetes mellitus and type 2 diabetes mellitus.
|
27181765 |
2016 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite the emerging consensus on the role of ZnT8 in glucose homeostasis, a recent genetic study in humans has unexpectedly identified loss-of-function SLC30A8 mutants that are associated with protection from diabetes.
|
25287711 |
2015 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dependence on ZnT8 of hypoxia-induced changes in cell survival may contribute to the actions of SLC30A8 variants on diabetes risk in humans.
|
24865615 |
2014 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies have previously identified variants in SLC30A8, encoding the zinc transporter ZnT8, associated with diabetes risk.
|
24675520 |
2014 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A registry-based group of 288 persistently autoantibody-positive (Ab(+)) offspring/siblings (aged 0-39 years) of known patients (Ab(+) against insulin, GAD, IA-2 and/or ZnT8) were typed for HLA-DQ, -A and -B and monitored from the first Ab(+) sample for development of diabetes within 5 years.
|
23712485 |
2013 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations between ZnT8 antibody (ZnT8A), phenotype and the genetic variant rs13266634 in the SLC30A8 gene have primarily been studied in patients with young-onset diabetes.
|
23061550 |
2013 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years.
|
22526605 |
2012 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed diabetes risk associated with zinc transporter-8 antibodies (ZnT8A), islet cell antibodies (ICA), and HLA type and age in relatives of people with type 1 diabetes with the standard biochemical autoantibodies (BAA) to insulin (IAA), GAD65 (GAD65A), and/or insulinoma-associated protein 2 antigen (IA-2A).
|
22446173 |
2012 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Autoimmunity Study in the Young (DAISY) followed prospectively for development of persistent IA (autoantibodies to insulin, GAD65, IA-2, or ZnT8 on at least two consecutive exams) and diabetes 1715 non-Hispanic white children at increased genetic risk for T1D.
|
22776074 |
2012 |